Iradimed Q2 2026 earnings: 3870 pump transition compresses margins

Iradimed (NASDAQ: IRMD) reported Q2 2026 revenue of $20.5 million, up a reported 0.5% year over year, while GAAP diluted EPS fell 9% from $0.45 to $0.41. Net income and gross margin declined as the company began the production ramp and commercial transition to its next-generation 3870 MRI-compatible IV pump, while lower capital spending helped free cash flow increase despite weaker operating cash flow.

Core financial results

Revenue was nearly unchanged, but cost of revenue rose to $5.3 million from $4.5 million. As a result, gross profit fell 5% and gross margin contracted by four percentage points.

Operating expenses declined to $8.8 million from $9.2 million, partially offsetting the gross-profit pressure. That was not enough to prevent operating income, net income, and both GAAP and non-GAAP EPS from declining.

Non-GAAP results exclude stock-based compensation expense, net of tax. The excluded amount was $0.6 million in both comparative quarters when rounded.

Business and product performance

Product categories diverged during the quarter. MRI-compatible IV infusion pump system revenue fell approximately 21%, coinciding with the transition from the older 3860 platform to the newly launched 3870 pump. Patient-monitor revenue increased approximately 12%, while disposables, maintenance agreements, and ferromagnetic detection systems also grew.

Total device revenue nevertheless declined because growth in monitors and detection systems did not fully offset the lower pump contribution. Domestic sales represented 82% of revenue, down from 89% a year earlier, although the company did not provide a reason for the geographic mix shift.

The 3870 transition pressured current margins before the expected revenue ramp

The quarter was Iradimed’s first sizable production ramp for the 3870 pump. Management said initial shipments met its plan, but the ramp involved expected startup inertia and manufacturing challenges. That helps explain why nearly flat consolidated revenue was accompanied by lower gross profit and a four-percentage-point contraction in gross margin.

Management expects production efficiency and gross margin to improve as experience and volumes increase during the second half of 2026. Bookings offer some support for that outlook: more than 70% of new pump orders used the four-pump “quad stack” configuration, which doubles the number of pump channels from the previous norm. Domestic monitor unit bookings also reached a record, though bookings still need to convert into recognized revenue.

Profitability, cash flow, and the balance sheet

Quarterly operating cash flow fell 23% to $5.9 million, with accounts receivable identified as a negative factor. Free cash flow moved in the opposite direction, rising to $5.5 million because capital expenditures declined to $0.4 million from $2.8 million. The prior-year period included approximately $2.1 million related to construction of the company’s corporate office and manufacturing facility.

Cash and cash equivalents increased to $59.1 million at June 30, 2026, from $51.2 million at December 31, 2025. Total liabilities declined to $13.2 million from $14.2 million over the same period. Iradimed also declared a regular quarterly dividend of $0.20 per share, payable August 28, 2026, to shareholders of record on August 14.

Guidance

Iradimed introduced Q3 2026 guidance and reaffirmed its full-year outlook. The Q3 revenue range implies a step-up from the second quarter, consistent with management’s expectation that 3870 revenue will ramp during the second half.

The non-GAAP EPS outlook excludes stock-based compensation expense, net of tax, estimated at approximately $0.6 million for Q3 and $2.5 million for the full year.

Recent insider transactions

The supplied insider-trading data contained nine recent records with complete transaction direction and value information, all of which were sales. One additional June 18 record for CFO John F. Glenn was omitted because no transaction direction, amount, or value was provided.

Risks investors should monitor

• 3870 manufacturing execution: The initial production ramp contributed to startup inefficiencies. Delays in achieving higher volumes and better efficiency could keep gross margin under pressure.
• Bookings conversion: The full-year outlook depends partly on a significant second-half 3870 revenue ramp. Pump and monitor bookings must still convert into shipments and recognized revenue.
• Product-mix pressure: Pump-system revenue fell approximately 21%, and growth in monitors, disposables, and other categories was only enough to keep total revenue roughly flat.
• Working-capital volatility: Accounts receivable weighed on quarterly operating cash flow. Continued receivables pressure could limit cash conversion even if reported earnings improve.

Summary

Iradimed’s Q2 2026 results reflected the cost of transitioning to the 3870 pump: consolidated revenue remained nearly flat, but lower pump sales and production startup inefficiencies reduced margins and earnings. Growth in monitors, disposables, and other categories provided an offset, while lower capital expenditures supported free cash flow. The central issue for the second half is whether rising 3870 volumes convert the company’s bookings into revenue and restore manufacturing efficiency as assumed in its reaffirmed full-year guidance.